Skip to main content
PMC home page
Thorax logoLink to Thorax
. 2004 Jan;59(1):26–30. doi: 10.1136/thx.2003.015297

Time course of action of two inhaled corticosteroids, fluticasone propionate and budesonide

K Phillips 1, J Oborne 1, S Lewis 1, T Harrison 1, A Tattersfield 1
PMCID: PMC1758859  PMID: 14694242

Abstract

Background: It is important to be able to compare the efficacy and systemic effects of inhaled corticosteroids but their slow onset of action makes it difficult to measure the maximum response to a given dose. Submaximal responses could be compared if the time course of action of the inhaled corticosteroids being compared was similar. We have compared the time course of action of fluticasone and budesonide, measuring response as change in the provocative dose of adenosine monophosphate causing a 20% fall in forced expiratory volume in 1 second (PD20AMP).

Methods: Eighteen subjects with mild asthma, aged 18–65, took part in a three way randomised crossover study. Subjects took fluticasone (1500 µg/day), budesonide (1600 µg/day), and placebo each for 4 weeks with a washout period of at least 2 weeks between treatments; PD20AMP and forced expiratory volume in 1 second (FEV1) were measured during and after treatment. The time taken to achieve 50% of the maximum response (T50%) was compared as a measure of onset of action.

Results: There was a progressive increase in PD20AMP during the 4 weeks of treatment with both fluticasone and budesonide but not placebo; the increase after 1 and 4 weeks was 2.28 and 4.50 doubling doses (DD) for fluticasone and 2.49 and 3.65 DD for budesonide. T50% was 9.3 days for fluticasone and 7.5 days for budesonide with a median difference between fluticasone and budesonide of 0.1 days (95% CI -1.4 to 2.65). There was a wide range of response to both inhaled corticosteroids but good correlation between the response to fluticasone and budesonide within subjects. FEV1 and morning peak expiratory flow rate (PEFR) increased during the first week of both active treatments and were stable thereafter. There was a small progressive improvement in nocturnal symptoms with both active treatments.

Conclusion: PD20AMP was a more sensitive marker of response to inhaled corticosteroid therapy than FEV1 and PEFR. The time course of action of fluticasone and budesonide on PD20AMP is similar, suggesting that comparative studies of their efficacy using 1 or 2 week treatment periods are valid. When a new inhaled corticosteroid becomes available, a pilot study comparing its time course of action with that of an established corticosteroid should allow comparative studies to be performed more efficiently.

Full Text

The Full Text of this article is available as a PDF (250.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bootsma G. P., Dekhuijzen P. N., Festen J., Mulder P. G., van Herwaarden C. L. Comparison of fluticasone propionate and beclomethasone dipropionate on direct and indirect measurements of bronchial hyperresponsiveness in patients with stable asthma. Thorax. 1995 Oct;50(10):1044–1050. doi: 10.1136/thx.50.10.1044. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cumming R. G., Mitchell P., Leeder S. R. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med. 1997 Jul 3;337(1):8–14. doi: 10.1056/NEJM199707033370102. [DOI] [PubMed] [Google Scholar]
  3. Doull l. J., Sandall D., Smith S., Schreiber J., Freezer N. J., Holgate S. T. Differential inhibitory effect of regular inhaled corticosteroid on airway responsiveness to adenosine 5' monophosphate, methacholine, and bradykinin in symptomatic children with recurrent wheeze. Pediatr Pulmonol. 1997 Jun;23(6):404–411. doi: 10.1002/(sici)1099-0496(199706)23:6<404::aid-ppul2>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  4. Garbe E., LeLorier J., Boivin J. F., Suissa S. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA. 1997 Mar 5;277(9):722–727. [PubMed] [Google Scholar]
  5. Haahtela T., Järvinen M., Kava T., Kiviranta K., Koskinen S., Lehtonen K., Nikander K., Persson T., Reinikainen K., Selroos O. Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med. 1991 Aug 8;325(6):388–392. doi: 10.1056/NEJM199108083250603. [DOI] [PubMed] [Google Scholar]
  6. Harrison T. W. Systemic availability of inhaled budesonide and fluticasone propionate: healthy versus asthmatic lungs. BioDrugs. 2001;15(6):405–411. doi: 10.2165/00063030-200115060-00006. [DOI] [PubMed] [Google Scholar]
  7. Hindle M., Newton D. A., Chrystyn H. Dry powder inhalers are bioequivalent to metered-dose inhalers. A study using a new urinary albuterol (salbutamol) assay technique. Chest. 1995 Mar;107(3):629–633. doi: 10.1378/chest.107.3.629. [DOI] [PubMed] [Google Scholar]
  8. Jenkins C. R., Woolcock A. J. Effect of prednisone and beclomethasone dipropionate on airway responsiveness in asthma: a comparative study. Thorax. 1988 May;43(5):378–384. doi: 10.1136/thx.43.5.378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Johnson M. Pharmacodynamics and pharmacokinetics of inhaled glucocorticoids. J Allergy Clin Immunol. 1996 Jan;97(1 Pt 2):169–176. doi: 10.1016/s0091-6749(96)80217-x. [DOI] [PubMed] [Google Scholar]
  10. Juniper E. F., Kline P. A., Vanzieleghem M. A., Ramsdale E. H., O'Byrne P. M., Hargreave F. E. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis. 1990 Oct;142(4):832–836. doi: 10.1164/ajrccm/142.4.832. [DOI] [PubMed] [Google Scholar]
  11. Meijer R. J., Kerstjens H. A., Arends L. R., Kauffman H. F., Koëter G. H., Postma D. S. Effects of inhaled fluticasone and oral prednisolone on clinical and inflammatory parameters in patients with asthma. Thorax. 1999 Oct;54(10):894–899. doi: 10.1136/thx.54.10.894. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Nielsen L. P., Dahl R. Therapeutic ratio of inhaled corticosteroids in adult asthma. A dose-range comparison between fluticasone propionate and budesonide, measuring their effect on bronchial hyperresponsiveness and adrenal cortex function. Am J Respir Crit Care Med. 2000 Dec;162(6):2053–2057. doi: 10.1164/ajrccm.162.6.9912072. [DOI] [PubMed] [Google Scholar]
  13. O'Connor B. J., Ridge S. M., Barnes P. J., Fuller R. W. Greater effect of inhaled budesonide on adenosine 5'-monophosphate-induced than on sodium-metabisulfite-induced bronchoconstriction in asthma. Am Rev Respir Dis. 1992 Sep;146(3):560–564. doi: 10.1164/ajrccm/146.3.560. [DOI] [PubMed] [Google Scholar]
  14. Phillips K., Oborne J., Harrison T. W., Tattersfield A. E. Use of sequential quadrupling dose regimens to study efficacy of inhaled corticosteroids in asthma. Thorax. 2004 Jan;59(1):21–25. doi: 10.1136/thx.2003.015289. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Pieters W. R., Stallaert R. A., Prins J., Greefhorst A. P., Bosman H. G., van Uffelen R., Schreurs A. J., van Helmond J. L., Janssen P. G. A study on the clinical equivalence and patient preference of fluticasone propionate 250 microg twice daily via the Diskus/Accuhaler inhaler or the Diskhaler inhaler in adult asthmatic patients. J Asthma. 1998;35(4):337–345. doi: 10.3109/02770909809075666. [DOI] [PubMed] [Google Scholar]
  16. Thorsson L., Edsbäcker S., Conradson T. B. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J. 1994 Oct;7(10):1839–1844. doi: 10.1183/09031936.94.07101839. [DOI] [PubMed] [Google Scholar]
  17. Vathenen A. S., Knox A. J., Wisniewski A., Tattersfield A. E. Time course of change in bronchial reactivity with an inhaled corticosteroid in asthma. Am Rev Respir Dis. 1991 Jun;143(6):1317–1321. doi: 10.1164/ajrccm/143.6.1317. [DOI] [PubMed] [Google Scholar]
  18. Weersink E. J., Douma R. R., Postma D. S., Koëter G. H. Fluticasone propionate, salmeterol xinafoate, and their combination in the treatment of nocturnal asthma. Am J Respir Crit Care Med. 1997 Apr;155(4):1241–1246. doi: 10.1164/ajrccm.155.4.9105061. [DOI] [PubMed] [Google Scholar]
  19. Wong C. A., Walsh L. J., Smith C. J., Wisniewski A. F., Lewis S. A., Hubbard R., Cawte S., Green D. J., Pringle M., Tattersfield A. E. Inhaled corticosteroid use and bone-mineral density in patients with asthma. Lancet. 2000 Apr 22;355(9213):1399–1403. doi: 10.1016/S0140-6736(00)02138-3. [DOI] [PubMed] [Google Scholar]
  20. van Velzen E., van den Bos J. W., Benckhuijsen J. A., van Essel T., de Bruijn R., Aalbers R. Effect of allergen avoidance at high altitude on direct and indirect bronchial hyperresponsiveness and markers of inflammation in children with allergic asthma. Thorax. 1996 Jun;51(6):582–584. doi: 10.1136/thx.51.6.582. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. van den Berge M., Kerstjens H. A., Meijer R. J., de Reus D. M., Koëter G. H., Kauffman H. F., Postma D. S. Corticosteroid-induced improvement in the PC20 of adenosine monophosphate is more closely associated with reduction in airway inflammation than improvement in the PC20 of methacholine. Am J Respir Crit Care Med. 2001 Oct 1;164(7):1127–1132. doi: 10.1164/ajrccm.164.7.2102135. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES